Sonablate, intended for use in the focused ablation of prostate tissue, first gained regulatory clearance in October 2015.
The new device contains an updated physical structure and software interface, offering new capabilities to monitor tissue changes and provide altered ultrasound delivery sequences, among other features.
SonaCare expects the new device to decrease overall procedure time by as much as 40 percent, according to a news release.
More articles on supply chain:
6 noteworthy drugs the FDA approved in 2016
HHS Sec. Burwell’s advice to Dr. Tom Price: Prioritize cybersecurity
Valeant to sell off $2B in assets to ease debt: 3 takeaways
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
